Lyell Immunopharma Boosts Solid Tumor Pipeline with Acquisition of Promising CAR T Therapy for…
Lyell Immunopharma, Inc., a late-stage clinical biotech company developing next-generation chimeric antigen receptor (CAR) T-cell therapies, has strengthened its solid tumor portfolio…
Read More...
Read More...
